Skip to main content

Table 1 Summary of patient characteristics from MT-04

From: Cost utility analysis of the SQ® HDM SLIT-tablet in house dust mite allergic asthma patients in a German setting

  Placebo ACARIZAX
No. of subjects 277 282
Sex (%)
 Male 151 (55 %) 147 (52 %)
 Female 126 (45 %) 135 (48 %)
Mean age (SD) 33.0 (12.2) 37 (11.6)
Ethnic origin (%)
 Caucasian 273 (99 %) 277 (98 %)
 Other 4 (1 %) 5 (2 %)
Mean years with HDM AA (SD) 13.3 (10.6) 12.9 (11.5)
Control level at randomisation (%)a
Controlled 0 (0 %) 0 (0 %)
 Partly controlled 200 (72 %) 200 (71 %)
 Uncontrolled 77 (28 %) 82 (29 %)
  1. AA allergic asthma, HDM house dust mite, SD standard deviation
  2. aClassification system based on GINA, Masoli et al. [2]